Bosquet et al. [50] described their research involving the p38 MAPK phosphorylation pathway, which is upstream of nuclear factor-kappaB (NF-κB) nuclear translocation and activation, the reduction of which is related to lipid-induced inflammation, and indicated that fatty acid binding protein 4 (FABP4) inhibitors could decrease saturated fatty acid-induced endoplasmic reticulum inflammation in skeletal muscle in diabetes mellitus patients. This evidence concerns the gene FABP4 and diabetes mellitus.